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Recent evidence suggests that the leukocytes (including 
stem cells) contained in organs migrate after transplantation 
and produce persistent chimerism, which is essential for 
sustained survival of the allografts (1, 2). With this informa-
tion, we proposed as an encompassing principle that success 
after either clinical bone marrow or organ transplantation 
"(whether described as) tolerance or graft acceptance means 
that a characteristic lymphoid and dendritic cell chimerism 
has been introduced which may be stable either without 
further treatment, or only when continued immunosuppres-
sion is provided" (1). Conversely, failure meant that "an 
unstable graft and its migrated cells may either be rejected or 
cause GVHD" (1). The same definitions have been phrased in 
different ways, such as: "Failure of the chimeric and recipient 
immunocytes to reach an immunological 'truce' leads to re-
jection of the transplanted whole organ on one hand, to 
GVHD on the other or sometimes to both simultaneously" (2). 
No modifications of the foregoing hypothesis have been 
mandated by further experimental or clinical evidence. How-
ever, misinterpretations of its meaning have been published 
in case reports of delayed acute liver allograft rejection 
caused by under immunosuppression (3-5). For example, in 
one recent study, the authors advised "exercise (oil restraint 
in accepting the suggestion that immunosuppression can be 
totally withdrawn in most patients due to chimerism-associ-
ated tolerance" (4, citing ref. 2). Other authors stated: "It has 
been proposed that the presence of lymphocytes of donor 
origin in the recipient blood and tissues, termed chimerism, 
may imply tolerance of the allograft and permit the with-
drawal of immunosuppression" (5, citing refs. 1 and 2). No 
such suggestions or proposals can be found in our cited arti-
cles (1,2). 
The opinions ascribed to us in the foregoing case reports 
are opposite to those actually expressed in our initial (1, 2) 
and all subsequent publications on the subject of chimerism 
(6, 7). Our contention throughout has been that chimerism is 
a necessary condition for organ allograft acceptance, but that 
it is not the same as tolerance (1,2, 6, 7). Chimerism and the 
derivative state of tolerance (if it is achieved) are almost 
contemporaneous in numerous rodent models, many of which 
do not even require immunosuppression when the trans-
planted organ is the liver (8). In contrast, what we postulated 
to be the cause (chimerism) and the effect (tolerance) are 
separated by months or years when liver transplantation is 
performed in outbred·animals and humans, no matter what 
the means of immunosuppression. In clinical practice, the 
time of mutual exposure of the two cell populations necessary 
to establish stability of drug-independent chimerism varies 
widely, as was demonstrated in the Pittsburgh clinical wean-
ing trials with liver recipients (9). 
The duration of this critical period and the amount of 
immunosuppression required during it to prevent one of the 
response arms from destroying the other must be detennined 
at present by trial and potential error. Although many liver 
recipients have stopped immunosuppression, the desired 
drug-free endpoint may never be achieved in some patients 
whose chimerism (and organ allografts) can nevertheless be 
maintained for a lifetime under continuous immunosuppres-
sion (1,2, 6, 7). The obvious folly has been believing that 
either the presence or the quantity of donor leukocyte chi-
merism can be used per se to guide decisions about drug 
weaning. 
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ACUTE REJECTION IN A RENAL TRANSPLANT PRECIPITATED BY PLASMAPHERESIS 
Focal segmental glomerulosclerosis can recur in up to 40% 
of patients after renal transplantation. A circulating factor in 
such patients has been shown to alter glomerular capillary 
permeability, and it can be removed with plasmapheresis (1). 
We recently treated a 28-year-old man with recurrent focal 
segmental glomerulosclerosis in a renal transplant using 
plasmapheresis (2). He received a cadaveric renal transplant 
in September 1994. Over the following 9 months. he was 
